334 related articles for article (PubMed ID: 32750253)
21. Bacterial Culture Underestimates Lung Pathogen Detection and Infection Status in Cystic Fibrosis.
Gavillet H; Hatfield L; Rivett D; Jones A; Maitra A; Horsley A; van der Gast C
Microbiol Spectr; 2022 Oct; 10(5):e0041922. PubMed ID: 35972283
[TBL] [Abstract][Full Text] [Related]
22. Interspecific small molecule interactions between clinical isolates of Pseudomonas aeruginosa and Staphylococcus aureus from adult cystic fibrosis patients.
Fugère A; Lalonde Séguin D; Mitchell G; Déziel E; Dekimpe V; Cantin AM; Frost E; Malouin F
PLoS One; 2014; 9(1):e86705. PubMed ID: 24466207
[TBL] [Abstract][Full Text] [Related]
23. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.
Tramper-Stranders GA; Wolfs TF; Fleer A; Kimpen JL; van der Ent CK
Pediatr Infect Dis J; 2007 Jan; 26(1):8-12. PubMed ID: 17195698
[TBL] [Abstract][Full Text] [Related]
24. Antimicrobial susceptibility of microorganisms isolated from sputum culture of patients with cystic fibrosis: Methicillin-resistant Staphylococcus aureus as a serious concern.
Mazloomi Nobandegani N; Mahmoudi S; Pourakbari B; Hosseinpour Sadeghi R; Najafi Sani M; Farahmand F; Motamed F; Nabavizadeh Rafsanjani R; Mamishi S
Microb Pathog; 2016 Nov; 100():201-204. PubMed ID: 27666507
[TBL] [Abstract][Full Text] [Related]
25. Microbiologic and therapeutic aspects of Staphylococcus aureus in cystic fibrosis patients.
Bauernfeind A; Hörl G; Przyklenk B
Scand J Gastroenterol Suppl; 1988; 143():99-102. PubMed ID: 3164518
[TBL] [Abstract][Full Text] [Related]
26. Bronchopulmonary infection-colonization patterns in Spanish cystic fibrosis patients: Results from a national multicenter study.
de Dios Caballero J; Del Campo R; Royuela A; Solé A; Máiz L; Olveira C; Quintana-Gallego E; de Gracia J; Cobo M; de la Pedrosa EG; Oliver A; Cantón R;
J Cyst Fibros; 2016 May; 15(3):357-65. PubMed ID: 26429520
[TBL] [Abstract][Full Text] [Related]
27. A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study.
Maliniak ML; Stecenko AA; McCarty NA
J Cyst Fibros; 2016 May; 15(3):350-6. PubMed ID: 26610860
[TBL] [Abstract][Full Text] [Related]
28. Exogenous Alginate Protects Staphylococcus aureus from Killing by Pseudomonas aeruginosa.
Price CE; Brown DG; Limoli DH; Phelan VV; O'Toole GA
J Bacteriol; 2020 Mar; 202(8):. PubMed ID: 31792010
[TBL] [Abstract][Full Text] [Related]
29.
Orazi G; O'Toole GA
mBio; 2017 Jul; 8(4):. PubMed ID: 28720732
[TBL] [Abstract][Full Text] [Related]
30. Colonization of CF patients' upper airways with S. aureus contributes more decisively to upper airway inflammation than P. aeruginosa.
Janhsen WK; Arnold C; Hentschel J; Lehmann T; Pfister W; Baier M; Böer K; Hünniger K; Kurzai O; Hipler UC; Mainz JG
Med Microbiol Immunol; 2016 Oct; 205(5):485-500. PubMed ID: 27377929
[TBL] [Abstract][Full Text] [Related]
31. A Pseudomonas aeruginosa Antimicrobial Affects the Biogeography but Not Fitness of Staphylococcus aureus during Coculture.
Barraza JP; Whiteley M
mBio; 2021 Mar; 12(2):. PubMed ID: 33785630
[No Abstract] [Full Text] [Related]
32. Changes in strategies for optimal antibacterial therapy in cystic fibrosis.
Ratjen F
Int J Antimicrob Agents; 2001 Feb; 17(2):93-6. PubMed ID: 11165111
[TBL] [Abstract][Full Text] [Related]
33. In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in CF patients.
Richards RM; Hamilton VE; Thomas MR
J Antimicrob Chemother; 1998 Aug; 42(2):171-8. PubMed ID: 9738834
[TBL] [Abstract][Full Text] [Related]
34. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.
Chmiel JF; Aksamit TR; Chotirmall SH; Dasenbrook EC; Elborn JS; LiPuma JJ; Ranganathan SC; Waters VJ; Ratjen FA
Ann Am Thorac Soc; 2014 Sep; 11(7):1120-9. PubMed ID: 25102221
[TBL] [Abstract][Full Text] [Related]
35. Polyclonality, Shared Strains, and Convergent Evolution in Chronic Cystic Fibrosis
Long DR; Wolter DJ; Lee M; Precit M; McLean K; Holmes E; Penewit K; Waalkes A; Hoffman LR; Salipante SJ
Am J Respir Crit Care Med; 2021 May; 203(9):1127-1137. PubMed ID: 33296290
[No Abstract] [Full Text] [Related]
36. The success of the different eradication therapy regimens for Pseudomonas aeruginosa in cystic fibrosis.
Emiralioglu N; Yalcin E; Meral A; Sener B; Dogru D; Ozcelik U; Kiper N
J Clin Pharm Ther; 2016 Aug; 41(4):419-23. PubMed ID: 27311742
[TBL] [Abstract][Full Text] [Related]
37. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis.
Smyth AR; Walters S
Cochrane Database Syst Rev; 2014 Nov; (11):CD001912. PubMed ID: 25419599
[TBL] [Abstract][Full Text] [Related]
38. Antimicrobial susceptibility and genotyping of microorganisms isolated from sputum culture of children with cystic fibrosis in an Iranian referral children's hospital.
Mamishi S; Akhlaghi A; Pourakbari B; Modaresi M; Haghi Ashtiani MT; Hosseinpour Sadeghi R; Shirzadi R; Shalchi Z; Mahmoudi S
Wien Med Wochenschr; 2023 May; 173(7-8):182-187. PubMed ID: 36167900
[TBL] [Abstract][Full Text] [Related]
39. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis.
Smyth AR; Rosenfeld M
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD001912. PubMed ID: 28417451
[TBL] [Abstract][Full Text] [Related]
40. Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor.
Singh SB; McLearn-Montz AJ; Milavetz F; Gates LK; Fox C; Murry LT; Sabus A; Porterfield HS; Fischer AJ
Pediatr Pulmonol; 2019 Aug; 54(8):1200-1208. PubMed ID: 31012285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
